Does My Reverse-Payment Settlement Violate the Antitrust Laws?

more+
less-

This article analyzes the antitrust exposure for reverse-payment settlement agreements between generic and brand-name pharmaceutical companies, by discussing relevant case law as well as FTC and Department of Justice positions.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Administrative Agency Updates, Antitrust & Trade Regulation Updates, Intellectual Property Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Jarod Bona, Bona Law PC | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »